From: Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
Characteristic* | Received first-line bevacizumab (n = 110) | Unadjusted p-value# |
---|---|---|
 | % |  |
Age (years) | Â | 0.007 |
< 55 | 41 | Â |
55-64 | 32 | Â |
65-74 | 30 | Â |
≥ 75 | 16 |  |
ACE-27 Comorbidity Index (score) | Â | 0.831 |
None (0) | 29 | Â |
Mild (1) | 30 | Â |
Moderate (2) | 35 | Â |
Severe (3) | 34 | Â |
Race | Â | 0.403 |
Non-white | 28 | Â |
White | 33 | Â |
Gender | Â | 0.005 |
Female | 41 | Â |
Male | 26 | Â |
Insurance | Â | 0.005 |
Private | 41 | Â |
Public | 20 | Â |
Medicare + supplemental | 32 | Â |
Veterans Administration | 21 | Â |
Missing | 21 | Â |
Health system | Â | 0.050 |
Fee-for-service | 35 | Â |
Integrated health system | 25 | Â |
Geographic region | Â | 0.003 |
West/Midwest | 23 | Â |
Southern | 35 | Â |
Atlantic | 43 | Â |
Annual household income | Â | 0.127 |
< $20,000/year | 25 | Â |
≥ $20,000/year | 34 |  |
Missing | 30 | Â |
Diagnosis of metastatic disease | Â | 0.532 |
Stage IV at diagnosis | 30 | Â |
Recurrence | 35 | Â |
Did anyone mention that enrollment in a clinical trial might be an option for you? | Â | 0.152 |
Yes | 38 | Â |
No | 28 | Â |
Missing | 35 | Â |
How often do you read books, magazines or newspapers? | Â | 0.111 |
Often | 35 | Â |
Rarely | 24 | Â |
Missing | 26 | Â |
After talking with your doctors about chemotherapy, how likely did you think it was that chemotherapy would have side-effects or complications? | Â | 0.133 |
Likely | 33 | Â |
Not likely | 24 | Â |
Missing | 30 | Â |